Search

Your search keyword '"Jakob, Clarissa"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Jakob, Clarissa" Remove constraint Author: "Jakob, Clarissa"
45 results on '"Jakob, Clarissa"'

Search Results

2. Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In VivoTarget Engagement

3. Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor

4. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

6. Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

8. 4-Amino-5-aryl-6-arylethynylpyrimidines: Structure–activity relationships of non-nucleoside adenosine kinase inhibitors

12. Structure-based Optimization of MurF Inhibitors

13. Ion binding induces closed conformation in Psuedomonas 7A glutaminase-asparaginase (PGA): crystal structure of the PGA-SO (sub 4)(super 2-)-NH4+ complex at 1.7 angstrom resolution

17. Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer

20. SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding

21. Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315

22. Abstract LB-A23: Discovery of a potent catalytic p300/CBP inhibitor that targets lineage-specific tumors

23. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

24. Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors

25. Erratum: The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

26. The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

27. The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity

28. Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2

29. Crystal Structures of Human Adenosine Kinase Inhibitor Complexes Reveal Two Distinct Binding Modes

30. Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer

31. Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation

32. A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

33. Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 Diabetes.

34. Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors

35. Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 Diabetes

36. Discovery of Potent Inhibitors of Dihydroneopterin Aldolase Using CrystaLEAD High-Throughput X-ray Crystallographic Screening and Structure-Directed Lead Optimization

37. Design, Synthesis, and Biological Activity of 4-[(4-Cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as Potent and Selective Farnesyltransferase Inhibitors

38. The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain

39. Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency

40. Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives

45. Crystal Structures of Human Adenosine Kinase Inhibitor Complexes Reveal Two Distinct Binding Modes

Catalog

Books, media, physical & digital resources